{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:16:31Z","timestamp":1760296591677},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":141,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2001,8]]},"abstract":"<jats:p>Strategies currently used for residual disease detection in acute lymphoblastic leukaemia (ALL) rely on polymerase chain reaction (PCR) detection of immunoglobulin and T\u2010cell receptor rearrangements. The TEL\u2013AML1 fusion transcript, which is associated with t(12;21) (p13;q22), is found in 25% of childhood B\u2010cell precursor ALL, and represents an interesting alternative target. We compared two methods for quantitating TEL\u2013AML1 fusion transcripts: competitive PCR and real\u2010time PCR. These techniques showed similar sensitivity (5\u2003\u00d7\u200310<jats:sup>\u22125<\/jats:sup>) and reproducibility. Giving highly correlated results, both techniques can be conveniently used for TEL\u2013AML1 transcript quantification. The constancy of TEL\u2013AML1 expression was evaluated by measuring TEL\u2013AML1 transcripts at different steps of the cell cycle, and in 21 cases of ALL at diagnosis. No major variation in TEL\u2013AML1 expression was observed during the cell cycle or in 20\/21 of the ALL patients. Residual disease was then determined after completion of induction therapy in 20 patients with a TEL\u2013AML1\u2010positive ALL. Seven patients out of 20 (35%) were still positive, including two patients with high level of residual blasts (close to or beyond 10<jats:sup>\u22122<\/jats:sup>). When comparison was possible, results obtained using TEL\u2013AML1 quantification were in accordance with those obtained using T\u2010cell receptor rearrangements analysis.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2001.02922.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:36:11Z","timestamp":1047364571000},"page":"281-289","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Quantification of TEL\u2013AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia"],"prefix":"10.1111","volume":"114","author":[{"given":"S\u00e9verine","family":"Drunat","sequence":"first","affiliation":[]},{"given":"Martine","family":"Olivi","sequence":"additional","affiliation":[]},{"given":"Ghislaine","family":"Brunie","sequence":"additional","affiliation":[]},{"given":"Bernard","family":"Grandchamp","sequence":"additional","affiliation":[]},{"given":"Etienne","family":"Vilmer","sequence":"additional","affiliation":[]},{"given":"Ivan","family":"Bi\u00e8che","sequence":"additional","affiliation":[]},{"given":"H\u00e9l\u00e8ne","family":"Cav\u00e9","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401858"},{"key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/clinchem\/45.8.1148","article-title":"Real\u2010time reverse transcription\u2010PCR assay for future management of ERBB2\u2010based clinical applications","volume":"45","author":"Bi\u00e8che I.","year":"1999","journal-title":"Clinical Chemistry"},{"key":"e_1_2_6_4_1","first-page":"452","article-title":"Quantitation of hTERT gene expression in sporadic breast tumors with a real\u2010time reverse transcription\u2010polymerase chain reaction assay","volume":"6","author":"Bi\u00e8che I.","year":"2000","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.2.571"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90988-1"},{"key":"e_1_2_6_7_1","first-page":"809","article-title":"PCR directly from stool samples: Usefulness of an internal standard","volume":"16","author":"Cav\u00e9 H.","year":"1994","journal-title":"Biotechniques"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1182\/blood.V83.7.1892.1892","article-title":"Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T\u2010cell receptor genes","volume":"83","author":"Cav\u00e9 H.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390904"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood.V88.1.302.302","article-title":"TEL\u2010AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B\u2010cell precursor acute lymphoblastic leukemia","volume":"88","author":"Cayuela J.M.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.1.6"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(97)10295-1"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.6.1929.1929"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2141.1999.01365.x","article-title":"Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis","volume":"105","author":"Foroni L.","year":"1999","journal-title":"British Journal of Haematology"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.2144\/99261rv01"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.7.2725"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1101\/gr.6.10.986"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.16.7276"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1101\/gr.4.6.357"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb06947.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401128"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00823.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1098-2264(199912)26:4<355::aid-gcc10>3.0.co;2-3"},{"key":"e_1_2_6_24_1","first-page":"106","article-title":"A simplified method for determination of specific DNA or RNA copy number using quantitative PCR and an automatic DNA sequencer","volume":"13","author":"Porcher C.","year":"1992","journal-title":"Biotechniques"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401426"},{"key":"e_1_2_6_26_1","first-page":"1094","article-title":"TEL\/AML1 gene fusion is related to in vitro drug sensitivity for l\u2010asparaginase in childhood acute lymphoblastic leukemia","volume":"96","author":"Ramakers\u2010van Woerden N.L.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.7.2891.bloodjournal8772891"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.11.4263.bloodjournal86114263"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.762712.x"},{"key":"e_1_2_6_30_1","first-page":"1985","article-title":"TEL\u2010AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis","volume":"9","author":"Shurtleff S.A.","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood.V95.3.815.003k30_815_819","article-title":"Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical reslapse","volume":"95","author":"Tobal K.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(98)04058-6"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401960"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401679"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401256"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02922.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02922.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2001.02922.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T18:58:09Z","timestamp":1704308289000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2001.02922.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["10.1046\/j.1365-2141.2001.02922.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02922.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8]]},"assertion":[{"value":"2001-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}